Yumeibo is a molecular pharmaceutical product developer, focusing on product research and service development in the direction of gene editing and exosome detection. It mainly provides safe biomedical products and technical services for laboratory research and clinical research. The main products are cells. Virus products, biochemical preparation products, molecular experimental products, etc. Recently, Yumeibo Bio received tens of millions of yuan in angel round financing from Linear Capital and Su Gaoxin Science and Technology Angel Fund, of which Linear Capital led the investment.
This article is reproduced from: https://www.itjuzi.com/investevent/13385486
This site is for inclusion only, and the copyright belongs to the original author.